Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward B Garon

Showing results (61-70 of 204) with videos related to

Pageof 21
Sort By:
The Lancet. Oncology|May 29, 2017
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trialNarek Shaverdian, Aaron E Lisberg, Krikor Bornazyan, et al.
JTO Clinical and Research Reports|February 2, 2024
RELAY, Erlotinib Plus Ramucirumab in Untreated, <i>EGFR</i>-Mutated, Metastatic NSCLC: Outcomes by <i>EGFR</i> Exon 19 Deletion VariantsKazumi Nishino, Jin-Yuan Shih, Kazuhiko Nakagawa, et al.
Clinical Lung Cancer|March 8, 2023
Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II StudyMelissa L Johnson, James Strauss, Manish R Patel, et al.
Clinical Lung Cancer|July 18, 2017
Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)Daria Gaut, Myung Shin Sim, Yuguang Yue, et al.
JCO Precision Oncology|September 10, 2025
Identification of Targetable <i>EGFR</i> Mutations in Ovarian CancerArjan Gower, Susan Win, Rituparna Ganguly, et al.
Critical Reviews in Oncogenesis|June 10, 2016
Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We ComeEdward B Garon, Phillip A Abarca, Jennifer L Strunck, et al.
Clinical Lung Cancer|May 9, 2025
Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking PatientsMichael S Oh, Edward B Garon, Aaron E Lisberg, et al.
Clinical Lung Cancer|April 19, 2023
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical OutcomeMakoto Nishio, Luis Paz-Ares, Martin Reck, et al.
JCO Clinical Cancer Informatics|January 18, 2019
Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial DocumentationCharlene M Fares, Timothy J Williamson, Matthew K Theisen, et al.
JTO Clinical and Research Reports|March 16, 2023
Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and OsimertinibClayton P Smith, Michael Xiang, Stephanie M Yoon, et al.
Pageof 21

Showing results (61-70 of 204) with videos related to

Sort By:
Pageof 21
The Lancet. Oncology|May 29, 2017
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trialNarek Shaverdian, Aaron E Lisberg, Krikor Bornazyan, et al.
JTO Clinical and Research Reports|February 2, 2024
RELAY, Erlotinib Plus Ramucirumab in Untreated, <i>EGFR</i>-Mutated, Metastatic NSCLC: Outcomes by <i>EGFR</i> Exon 19 Deletion VariantsKazumi Nishino, Jin-Yuan Shih, Kazuhiko Nakagawa, et al.
Clinical Lung Cancer|March 8, 2023
Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II StudyMelissa L Johnson, James Strauss, Manish R Patel, et al.
Clinical Lung Cancer|July 18, 2017
Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)Daria Gaut, Myung Shin Sim, Yuguang Yue, et al.
JCO Precision Oncology|September 10, 2025
Identification of Targetable <i>EGFR</i> Mutations in Ovarian CancerArjan Gower, Susan Win, Rituparna Ganguly, et al.
Critical Reviews in Oncogenesis|June 10, 2016
Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We ComeEdward B Garon, Phillip A Abarca, Jennifer L Strunck, et al.
Clinical Lung Cancer|May 9, 2025
Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking PatientsMichael S Oh, Edward B Garon, Aaron E Lisberg, et al.
Clinical Lung Cancer|April 19, 2023
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical OutcomeMakoto Nishio, Luis Paz-Ares, Martin Reck, et al.
JCO Clinical Cancer Informatics|January 18, 2019
Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial DocumentationCharlene M Fares, Timothy J Williamson, Matthew K Theisen, et al.
JTO Clinical and Research Reports|March 16, 2023
Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and OsimertinibClayton P Smith, Michael Xiang, Stephanie M Yoon, et al.
Pageof 21